Heat Biologics Quote - HTBX

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.38

Bid

Offer

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

62.075M

Previous Close

2.38

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

26,082,000

Dividend Yield

PE Ratio

-0.13

Earnings Per Share (EPS)

-1.73

Revenue

Net Profit

-45.22M

Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy and Comb... Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically modified, irradiated human cancer cells that secrete tumour-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ir.scorpiusbiologics.com/

Headquarters

Wilmington, Delaware, USA

Founded

NightHawk Biosciences Provides First Quarter 2022 Business Update

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to...

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to...

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing...

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on...

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American:...

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and...

REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments

DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...

Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas today at 11:00am ET/ 10:00am CT today at...

Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...

Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

HTBX - Frequently Asked Questions (FAQ)

What is the current Heat Biologics share price?

The current share price of Heat Biologics is US$ 2.38

How many Heat Biologics shares are in issue?

Heat Biologics has 26,082,000 shares in issue

What is the market cap of Heat Biologics?

The market capitalisation of Heat Biologics is USD 62.08M

What is the 1 year trading range for Heat Biologics share price?

Heat Biologics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Heat Biologics?

The price to earnings ratio of Heat Biologics is -0.13

What is the cash to sales ratio of Heat Biologics?

The cash to sales ratio of Heat Biologics is 0.82

What is the reporting currency for Heat Biologics?

Heat Biologics reports financial results in USD

What is the latest annual turnover for Heat Biologics?

The latest annual turnover of Heat Biologics is USD 7M

What is the latest annual profit for Heat Biologics?

The latest annual profit of Heat Biologics is USD -45.22M

What is the registered address of Heat Biologics?

The registered address for Heat Biologics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Heat Biologics website address?

The website address for Heat Biologics is ir.scorpiusbiologics.com/

Which industry sector does Heat Biologics operate in?

Heat Biologics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LIAEStone Ridge 2050 Inflation-Protected Longevity Income ETF	US$ 173.096 (900.00%)	2
LFAIStone Ridge 2050 Longevity Income ETF	US$ 132.05 (900.00%)	3
LFAEStone Ridge 2048 Longevity Income ETF	US$ 121.596 (900.00%)	21
LIACStone Ridge 2049 Inflation-Protected Longevity Income ETF	US$ 164.999 (900.00%)	10
LFAFStone Ridge 2049 Longevity Income ETF	US$ 126.796 (900.00%)	7
CHROChannel Therapeutics Corporation	US$ 1.28 (-18.99%)	139.81k
AZTRAzitra Inc	US$ 0.3418 (-11.52%)	2.91M
CLDICalidi Biotherapeutics Inc	US$ 1.3099 (-11.49%)	2.38M
MPUMega Matrix Inc	US$ 0.8549 (-11.01%)	206.73k
SCPXScorpius Holdings Inc	US$ 0.2198 (-10.50%)	699.03k
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 26.33 (-4.91%)	87.91M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 5.8796 (2.97%)	80.97M
FXIiShares China Large Cap	US$ 32.735 (1.41%)	73.25M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 2.85 (7.14%)	67.49M
ETHU2x Ether ETF	US$ 4.083 (-10.26%)	53.99M